한글목차

숙신산 메토프롤롤 세계 시장은 2024년에 3억 8,291만 달러로 평가되며, 예측 기간 동안 6.86%의 CAGR로 2030년에는 7억 4,529만 달러에 달할 것으로 예상됩니다.

선택적 베타차단제인 숙신산 메토프롤롤은 고혈압, 만성 심부전, 협심증, 부정맥과 같은 심혈관질환의 관리에 널리 사용되고 있습니다. 메토프롤롤은 장기간 지속되는 약효와 임상적 효과로 인해 장기적인 치료제로 선호되고 있습니다. 전 세계적으로 심혈관질환에 대한 부담 증가, 의료에 대한 인식 증가, 비용 효율적인 치료에 대한 수요 증가가 시장을 주도하고 있습니다. 특허 만료에 따른 제네릭 의약품의 등장은 특히 개발도상국에서 저렴한 가격과 접근성 향상을 가져왔습니다. 또한, 치료 성과와 환자 순응도를 높이기 위해 의료 업계가 병용요법을 강조하고 있는 것도 숙신산 메토프롤롤에 대한 수요를 더욱 촉진하고 있습니다.

시장 촉진요인

제약 산업의 성장

시장의 과제

부작용 및 소송 위험

주요 시장 동향

서방형 제제에 대한 선호도 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 숙신산 메토프롤롤 시장에 미치는 영향

제5장 세계의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 판매 채널별(직접, 간접)
  • 용도별(고혈압, 만성 심부전, 협심증, 부정맥, 불안증, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 숙신산 메토프롤롤 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 숙신산 메토프롤롤 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Granules India Limited
• Surya Remedies Private Limited
• Shubham Remedies
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
• ATUL BIOSCIENCE LTD
• UNITED CHEMIE PVT LTD
• Vasoya Industries Pvt. Ltd
• Infocus Remedies Pvt Ltd
• Alembic Pharmaceuticals Ltd

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

Global Metoprolol Succinate Market was valued at USD 382.91 Million in 2024 and is expected to reach USD 745.29 Million by 2030 with a CAGR of 6.86% during the forecast period. Metoprolol succinate, a selective beta-blocker, is widely utilized for managing cardiovascular conditions such as hypertension, chronic heart failure, angina pectoris, and arrhythmias. Its long-acting profile and clinical efficacy make it a preferred option for long-term treatment. The increasing global burden of cardiovascular diseases, coupled with growing healthcare awareness and rising demand for cost-effective therapies, is significantly driving the market. The availability of generic alternatives following patent expirations has improved affordability and expanded access, particularly in developing countries. Moreover, the healthcare industry's emphasis on combination therapies to enhance treatment outcomes and patient compliance is further propelling demand for metoprolol succinate.

Key Market Drivers

Growth in Pharmaceutical Industry

The continuous expansion of the global pharmaceutical sector is a major catalyst for the growth of the metoprolol succinate market. With pharmaceutical revenues reaching approximately USD 1.6 trillion in 2023, the industry's size has become comparable to the GDP of large national economies. This growth is primarily attributed to the rising prevalence of cardiovascular diseases and other chronic conditions. Lifestyle-related risk factors, such as sedentary habits, unhealthy diets, and an aging global population, have led to a surge in hypertension and heart-related disorders. Cardiovascular diseases, which account for nearly 17.9 million deaths annually, have made beta-blockers like metoprolol succinate an essential component of treatment regimens. The demand for metoprolol succinate continues to rise as pharmaceutical companies increase production capacity and focus on developing user-friendly formulations, such as extended-release tablets, to improve compliance and outcomes.

Key Market Challenges

Adverse Drug Reactions and Litigation Risks

Despite its widespread use, metoprolol succinate is associated with certain adverse drug reactions (ADRs), which can impact its adoption and market perception. Common side effects include fatigue, dizziness, hypotension, and bradycardia, while rare but serious complications such as bronchospasm and heart block may also occur. These reactions, especially when experienced by patients managing long-term therapy, can raise safety concerns and lead to treatment discontinuation. Moreover, the occurrence of ADRs has contributed to an increase in legal challenges and liability risks for pharmaceutical companies. Lawsuits stemming from drug-related injuries or inadequate warnings can damage corporate reputation and lead to significant financial penalties. As a result, managing drug safety, ensuring transparent communication about side effects, and maintaining compliance with regulatory standards are critical to sustaining trust and market stability.

Key Market Trends

Growing Preference for Extended-Release Formulations

A notable trend in the metoprolol succinate market is the increasing shift toward extended-release (ER) formulations, which are designed to maintain consistent therapeutic levels over a 24-hour period. Products like TOPROL-XL exemplify this trend, offering once-daily dosing that enhances patient convenience and treatment adherence. ER formulations reduce the likelihood of missed doses and provide more stable blood pressure control, which is especially beneficial for individuals managing chronic cardiovascular conditions. The convenience and effectiveness of extended-release tablets make them a preferred option among both physicians and patients. This shift also aligns with the broader healthcare emphasis on long-term disease management and patient-centric care models, further supporting the adoption of ER versions of metoprolol succinate in clinical practice.

Key Market Players

• Granules India Limited
• Surya Remedies Private Limited
• Shubham Remedies
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
• ATUL BIOSCIENCE LTD
• UNITED CHEMIE PVT LTD
• Vasoya Industries Pvt. Ltd
• Infocus Remedies Pvt Ltd
• Alembic Pharmaceuticals Ltd

Report Scope:

In this report, the Global Metoprolol Succinate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metoprolol Succinate Market, By Sales Channel:

• Direct
• Indirect

Metoprolol Succinate Market, By End Use:

• Hypertension
• Chronic Heart Failure
• Angina Pectoris
• Arrhythmias
• Anxiety
• Others

Metoprolol Succinate Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metoprolol Succinate Market.

Available Customizations:

Global Metoprolol Succinate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Metoprolol Succinate Market

5. Global Metoprolol Succinate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Hypertension, Chronic Heart Failure, Angina Pectoris, Arrhythmias, Anxiety, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Metoprolol Succinate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metoprolol Succinate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Metoprolol Succinate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Metoprolol Succinate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Metoprolol Succinate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Metoprolol Succinate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Metoprolol Succinate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Metoprolol Succinate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Metoprolol Succinate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Metoprolol Succinate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Metoprolol Succinate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Metoprolol Succinate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Metoprolol Succinate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Metoprolol Succinate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Metoprolol Succinate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Metoprolol Succinate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Metoprolol Succinate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metoprolol Succinate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Metoprolol Succinate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Metoprolol Succinate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Metoprolol Succinate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metoprolol Succinate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Metoprolol Succinate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Metoprolol Succinate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Metoprolol Succinate Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Granules India Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Surya Remedies Private Limited
• 15.3. Shubham Remedies
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Dr. Reddy's Laboratories
• 15.6. ATUL BIOSCIENCE LTD
• 15.7. UNITED CHEMIE PVT LTD
• 15.8. Vasoya Industries Pvt. Ltd
• 15.9. Infocus Remedies Pvt Ltd
• 15.10. Alembic Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer